Radiation Exposure

Pipeline Programs

Companies

Clinical Trials

1 recruiting

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

BraccoItaly - Milan

2 programs

CardioGen-82N/A1 trial

Active Trials

NCT01430975Completed72Est. Mar 2012

NCT01424774Completed155Est. Apr 2012

Rampart HealthCA - San Diego

1 program

RadiationN/A1 trial

Active Trials

NCT06875583Recruiting100Est. Mar 2026

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

Rampart HealthRadiation

BraccoCardioGen-82

Clinical Trials (3)

Total enrollment: 327 patients across 3 trials

NCT06875583 Rampart HealthRadiation

The Radiation ProtEction for Dose RedUction in the Cardiac CathEter Lab Study: The REDUCE Trial

Start: Aug 2025Est. completion: Mar 2026100 patients

N/ARecruiting

NCT01430975 BraccoCardioGen-82

Prospective Evaluation of Strontium in Patients After CardioGen-82 PET MPI Scanning at Two Clinical Sites

Start: Sep 2011Est. completion: Mar 201272 patients

N/ACompleted

NCT01424774 BraccoCardioGen-82

Prospective Evaluation of Strontium in Patients After CardioGen-82 PET MPI Scanning

Start: Sep 2011Est. completion: Apr 2012155 patients

N/ACompleted

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 327 patients

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.